Teva makes South Korean joint venture agreement

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Teva makes South Korean joint venture agreement

Home/Pharma News | Posted 11/01/2013 0 Post your comment

Teva Pharmaceutical Industries (Teva) announced on 16 December 2012 that it had made an agreement with Handok Pharmaceuticals (Handok) to establish a business venture in South Korea.

Under the terms of the agreement, the Israel-based generics giant will contribute its global resources, and be responsible for manufacturing and supplying a wide range of affordable and innovative medicines. South Korean Handok will be responsible for sales and marketing, distribution and regulatory affairs.

Teva will have a controlling stake in the new venture, gaining 51% of generated profits. The joint venture is expected to commence activities in the next few months, subject to receipt of applicable regulatory approvals. Financial details have not been disclosed.

The deal is Teva’s first in East Asian territory outside Japan and ‘is another significant step’ in Teva’s strategy to expand its presence in growing markets, according to Mr Itzhak Krinsky, Chairman of Teva Japan, Chairman of Teva South Korea and Head of Business Development Asia Pacific.

Mr Krinsky expects that Teva’s broad portfolio [including the multiple sclerosis blockbuster Copaxone (glatiramer acetate) and its branded generics], along with its R & D capabilities and its global infrastructure and know-how coupled with Handok’s expertise and strong reputation in South Korea, will enable the companies ‘to assume a prominent position in the Korean pharmaceutical market’.

Mr Young-Jin Kim, Handok’s Chief Executive Officer, said the venture is expected to ‘contribute greatly to the Korean pharmaceutical industry by supplying medicines at more affordable prices and providing innovative treatment solutions for central nervous system, respiratory and women’s health’.

The agreement will expand Teva’s presence in Asia and enable Teva to gain entrance to the Korean pharmaceutical market, valued at approximately US$14 billion.

Related articles

Teva cost-cutting and re-organization

Teva outlines expansion plans in Asia

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Handok, Teva